Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 7/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24384232 | 0.87 | CXCR4 (0.49) | CXCR4HIF1ASIGMAR1PRMT5KDM5C | |
| SCHEMBL26885910 | 0.84 | CXCR4 (0.46) | CXCR4HIF1ASIGMAR1PRMT5KDM5C | |
| SCHEMBL24384235 | 0.77 | CXCR4 (0.40) | CXCR4HIF1APRMT5CSF1RKDM4E | |
| SCHEMBL26089776 | 0.77 | KDM4E (0.38) | CXCR4LMNAKDM4EALDH1A1CHRM3 | |
| SCHEMBL16093362 | 0.74 | CXCR4 (0.69) | CXCR4SIGMAR1PRMT5KDM5CKDM4C | |
| SCHEMBL1089502 | 0.74 | CXCR4 (0.65) | CXCR4SIGMAR1KDM5CKDM4CLMNA | |
| SCHEMBL17996820 | 0.74 | CXCR4 (0.65) | CXCR4SIGMAR1KDM5CKDM4CLMNA | |
| Bromide SCHEMBL29604778 | 0.73 | CXCR4 (0.78) | CXCR4SIGMAR1KDM5CKDM4CLMNA | |
| Hydrochloric Acid SCHEMBL5570623 | 0.73 | CXCR4 (0.78) | CXCR4SIGMAR1KDM5CKDM4CLMNA | |
| Hydrochloric Acid SCHEMBL29604268 | 0.73 | CXCR4 (0.78) | CXCR4SIGMAR1KDM5CKDM4CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222143-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2023070004-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250222143-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | PAICS, RABGGTB, PARP1 | CXCR4 7/4885HIF1A 2288/4885SIGMAR1 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.